Effects of hepato-preferential basal insulin peglispro on nuclear magnetic resonance biomarkers lipoprotein insulin resistance index and GlycA in patients with diabetes

What Was Tested

This clinical trial, phase iii paper looks at Insulin Glargine in the context of insulin resistance, prediabetes & type 2 diabetes.

To characterize the effects of hepato-preferential basal insulin peglispro (BIL) and insulin glargine on insulin resistance (lipoprotein insulin resistance index [LP-IR]) and inflammation (GlycA), and to explore the biological implications.

Who Took Part

According to the abstract, 847 patients were involved.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

This substudy included 847 patients with Type 1 diabetes (T1D) or Type 2 diabetes (T2D) in four cohorts of the BIL development program.

LP-IR and GlycA were measured before and after insulin treatment.

How the Study Was Run

Correlations between LP-IR, GlycA, clinical parameters and liver biomarkers were assessed.

What Was Measured

The subject headings attached to it are Biomarkers, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Insulin Glargine, Insulin Resistance and Lipoproteins.

Author keywords: BIL, CK-18, ELF score, GlycA, LP-IR score and Type 2 diabetes.

What This Means in Plain Language

This is a clinical trial, phase iii of Insulin Glargine in 847 patients in people with insulin resistance, prediabetes & type 2 diabetes.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Biomarkers in medicine), a journal based in England.

More context: the Insulin Glargine compound page, Insulin resistance, prediabetes & type 2 diabetes research.